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ABSTRACT 
AIMS 
To determine whether beta-blockers, aspirin, and statins are underutilized after first-time myocardial infarction (MI) 
in patients with chronic obstructive pulmonary disease (COPD) compared with patients without COPD. Further, to 
determine temporal trends, and risk factors for non-use. 
METHODS AND RESULTS 
Using Danish nationwide registers, we performed a cross-sectional study investigating the utilization of beta-
blockers, aspirin and statins after hospitalisation for first-time MI among patients with and without COPD from 1995 
to 2015. Risk factors for non-use were examined in multivariable logistic regression models.  
During 21 years of study, 140,278 patients were included, hereof 13,496 (9.6%) with COPD. 
Patients with COPD were less likely to use beta-blockers (53.2% vs. 76.2%, P<0.001), aspirin (73.9% vs. 78.8%, 
P<0.001), and statins (53.5% vs. 61.9%, P<0.001). Medication usage increased during the study period but in 
multivariable analyses, COPD remained a significant predictor for non-use: OR [95% CI] for non-use of beta-
blockers 1.86 [1.76-1.97]; aspirin 1.24 [1.16-1.32]; statins 1.50 [1.41-1.59]. Analyses stratified by ST-segment 
elevation myocardial infarction (STEMI) and non-STEMI showed similar undertreatment of COPD patients.  
Risk factors for non-use of beta-blockers in COPD included increasing age, female sex, and 
increasing severity of COPD (frequent exacerbations, use of multiple inhaled medications, low lung function). 
Similar findings were demonstrated for aspirin and statins.  
CONCLUSION 
Beta-blockers, and to a lesser extent aspirin and statins, were systematically underutilized by patients with COPD 
following hospitalisation for MI despite an overall increase in the utilization over time. Increasing severity of COPD 
was a risk factor for non-use of the medications. 
KEYWORDS 
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Myocardial infarction; Chronic obstructive pulmonary disease; Secondary prevention; Beta-blockers; Aspirin; 
Statins. 
INTRODUCTION 
Ischemic heart disease is a common comorbidity in chronic obstructive pulmonary disease (COPD) contributing 
significantly to morbidity and mortality.1 Following myocardial infarction (MI), secondary prevention with beta-
blockers, aspirin and statins reduces mortality and reinfarction.2–4 However, it has consistently been shown that 
COPD patients in the period during hospitalisation for MI and up to discharge do not receive secondary prevention 
medication as recommended. The extent of the undertreatment varies between countries and time periods but is 
consistent.5–12 In contrast, knowledge about medication usage following discharge from hospitalisation for MI is 
scarce. Undertreatment with beta-blockers might be related to concerns about bronchoconstriction,13 yet few studies 
have investigated COPD-related factors associated with non-use of secondary prevention medications in COPD,6,7 
and data on lung function and symptom severity were available in only one study.7  
Using Danish nationwide registers, we can study medication usage following hospitalisation, 
temporal trends over long time periods, and factors related to non-use of medications such as demographics, 
comorbidities, COPD severity, and socioeconomic status, which may explain some of the differences in treatment. 
We aimed to investigate the utilization of beta-blockers, aspirin and statins among Danish patients with COPD 
following hospitalization for first-time MI compared with patients without COPD. Furthermore, we investigated 
temporal trends of medication usage from 1995 to 2015, and examined factors associated with medication non-use 
among patients with COPD. 
 
METHODS 
Design and data sources 
We performed a nationwide cross-sectional study using data from Danish national registers. In Denmark, a unique 
civil registration number is assigned to all residents at birth or immigration enabling cross-linkage between registers.  
We included data on prescription redemptions from The Danish Registry of Medicinal Product Statistics (a national 
prescription registry), hospital diagnoses from The Danish National Patient Register,14 vital and emigration status 
from The Danish Civil Register,15 and household income from Statistics Denmark.16 
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For clinical characterization of the patients, we used clinical data from the Danish Register of 
COPD, which is a nationwide database initiated January 1, 2008.17 It comprises data on forced expiratory volume in 
1 second expressed as percentage of predicted (FEV1%), severity of dyspnoea assessed with the modified Medical 
Research Council (mMRC) dyspnoea score, smoking status, and body mass index (BMI) which are obtained during 
outpatient visits in COPD hospital clinics.  
 
Population and medication 
All patients hospitalised with first-time MI between 1995 and 2015 were eligible for inclusion. Diagnosis of first-
time MI (ICD10 I21) have high validity in Danish registers with a positive predictive value (PPV) of 97%.18 From 
the MI diagnoses we stratified the population into three groups: ST-segment elevation MI (STEMI) using the 
validated diagnose codes ICD10 I210B, I211B, I213;18 non-STEMI (NSTEMI) (ICD10: I210A, I211A, I214);18 and 
unspecified, which were individuals with a diagnosis of MI but where the diagnosis was not validated for type of MI.  
We excluded patients who died or emigrated within 90 days from discharge to obtain a homogenous population of 
MI-survivors accessible for secondary preventive treatment. Further, patients with missing data on income were 
excluded. All other variables were complete.  
The utilization of secondary prevention medication after MI was determined within 90 days after 
discharge from hospital, and was defined as ≥1 redeemed prescriptions on beta-blockers, aspirin, and/or statins. The 
90 day observation period was chosen to allow prescriptions that had been redeemed late after discharge to be 
included in the analysis. Prior medication usage was determined during a period of 180 days prior to first MI. ATC 
codes are listed in Supplementary material, Table S2. 
 
COPD, clinical data, and exacerbations 
The COPD population was defined as individuals with diagnosis of COPD (ICD10: J42 - J44; ICD8: 491-492) from 
hospital admissions or outpatient visits from 1977 to first MI. Diagnosis of COPD in Danish registers has been 
validated and has a PPV of 92%.19 
Exacerbations of COPD prior to first MI were defined as ≥1 redeemed prescription of oral 
corticosteroids.20 To be considered as independent exacerbations, they had to be at least 28 days apart. In accordance 
with the Global Initiative for Chronic Obstructive Lung Disease (GOLD),21 we defined frequent exacerbations as ≥2 
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exacerbations and/or ≥1 hospital admission with COPD one year prior to first MI as defined in Supplementary 
material, Table S1.  
Clinical data from Danish Register of COPD prior to first MI were included in the analyses. If no 
observations prior to first MI were available, we allowed observations registered up to 90 days after first MI to be 
included. FEV1% was categorised according to the GOLD classification of airflow limitation severity (GOLD 1 - 
mild: FEV1% ≥ 80; GOLD 2 - moderate: 50 ≤FEV1% <80; GOLD 3 - severe: 30 ≤FEV1% <50; GOLD 4 - very 
severe: FEV1% <30).21 
 
Comorbidities and socioeconomic status 
Comorbidities were identified during a period of 10 years prior to first MI, based on diagnoses from hospital 
admissions and outpatient visits. Comorbidities are listed in Table 1, and definitions, ICD and ATC codes are shown 
in Supplementary material, Table S1. 
We included income to describe socioeconomic status of the patients. Income was calculated as the 
average household size adjusted disposable income of five years prior to first MI, categorised into tertiles within the 
study population (low, middle, and high).  
 
Statistical analyses 
First, we analysed the utilization of secondary prevention medications in the total study population stratified by the 
presence of COPD. Continuous variables were summarised using median and interquartile range (IQR) and 
compared using Wilcoxon rank-sum test, and categorical variables were summarised using percentages and 
compared using Pearson's chi-squared test. A P value of <0.05 was considered significant. 
Second, temporal trends in medication usage from 1995 to 2015 were plotted with 95% confidence 
intervals while stratifying for the presence of COPD.  
Third, we examined factors associated with non-use of medications using multivariable logistic 
regression models to estimate odds ratios and 95% confidence intervals (CI). The analyses were stratified into two 
time periods, 1995-2005 and 2006-2015, due to interaction between year of first MI and the association between 
COPD and medication non-use. Analyses from 2006 to 2015 were of primary interest, whereas analyses from 1995 
to 2005 were presented in the supplemental material. We first estimated the association between COPD and 
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medication non-use in the total study population adjusting for the following prechosen factors: age, sex, presence of 
heart failure, atrial fibrillation, angina pectoris, hypertension, diabetes, peripheral vascular disease, stroke, cancer, 
renal failure, asthma, or depression, and income. Next, analysing patients with COPD, we identified factors 
associated with medication non-use using the regression model described above.  
Further, in a subpopulation of patients with complete clinical data available from the Danish 
Register of COPD, we analysed the associations between medication non-use and GOLD class, mMRC dyspnoea 
score, BMI, and smoking status. This analysis was not stratified by time period, as the covariates from Danish 
Register of COPD were available only since 2008.  
In sensitivity analyses, we stratified the population in STEMI and NSTEMI. These analyses included 
characteristics of patients, temporal trends of medication usage, and regression analyses of factors associated with 
medication non-use in COPD. These analyses were performed to account for differences in indication for beta-
blockers according to type of presentation of MI.22 Sensitivity analyses also included univariable regression analyses 
of factors associated with non-use of medications in patients with clinical data available from the Danish Register of 
COPD.  
Regression models were tested for potential multicollinearity problems by estimating variance 
inflation factors. Data were managed with SAS 9.4 (SAS Institute, Cary, NC), and analysed with Stata/MP 15.1 
(StataCorp LP, College Station, TX). 
 
Ethics 
Ethical approval is not required for register-based studies in Denmark. The Danish Data Protection Agency approved 
the study (reference No. 2008-58-0020 / REG-11-2016). Anonymized data were made available to us so individuals 
could not be identified.  
 
Role of the funding source 
The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in the study and had final responsibility for the decision to 
submit for publication. 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjqcco/advance-article-abstract/doi/10.1093/ehjqcco/qcy063/5273489 by Aalborg U
niversity Library user on 10 January 2019
 
 
 
7 
 
 
RESULTS 
Characteristics 
A total of 140,278 patients with first-time MI were included in the study. Selection of the study population is shown 
in Figure 1. A total of 13,496 (9.6%) had COPD (Table 1). Compared to patients without COPD, patients with 
COPD were older, more often women and more likely to have comorbidities, especially heart failure, atrial 
fibrillation, peripheral vascular disease, and depression. Medication usage prior to first MI was higher in COPD 
regarding aspirin and statins, however only marginally higher for beta-blockers. Income was lower in COPD. A total 
of 65,645 patients had a diagnosis allowing for differentiation between STEMI and NSTEMI, and among those 
19,939 (30.4%) had STEMI, and 45,706 (69.6%) NSTEMI (supplementary Table S3).  
 
Utilization of secondary prevention medications 
During the 21 year study period, a total of 53.2% patients with COPD used beta-blockers after first MI, whereas 
76.2% of patients without COPD used beta-blockers (Table 1). Aspirin and statins were also underused in COPD, 
but to a lesser extent than beta-blockers. Sensitivity analyses of patients with validated diagnoses of STEMI and 
NSTEMI showed similar undertreatment in COPD (supplementary Table S3). 
Characteristics of patients with COPD according to usage of secondary prevention medication are 
presented in Table 2. Compared to non-users, beta-blocker users were marginally younger, more likely to be male, 
more likely to have used cardiovascular medications including beta-blockers prior to first MI, and more likely to 
have concurrent cardiac disease, hypertension, diabetes, peripheral vascular disease, and renal failure. Further, beta-
blocker users had less asthma and depression, fewer had frequent COPD exacerbations, and their usage of long-
acting inhaled medications was lower.  
The majority of beta-blockers utilized in both non-COPD and COPD were beta-1-selective and there 
was no distinct pattern in the usage of specific types of beta-blockers in non-COPD and COPD although the 
differences were statistically significant: beta-1-selective betablockers 88,705(91.8%) in non-COPD vs. 
6,415(89.3%) in COPD, P<0.001; alpha-beta-blockers 6,684(6.9%) vs. 751(10.5%), P<0.001; non-selective beta-
blockers 2,942(3.0%) vs. 151(2.1), P<0.001. The total percentage in this analysis adds up to more than 100% 
because some patients redeemed more than one prescription on beta-blockers. 
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Temporal trends of secondary prevention medication 
Temporal trends of beta-blocker, aspirin, statin usage in patients with and without COPD are 
presented in Figures 2a - 2c. Beta-blocker usage was significantly lower in patients with COPD throughout the study 
period. In non-COPD the usage increased rapidly from 45.8% in 1995 to 81.6% in 2001, where it stayed consistent 
until 2011-2012 where it decreased slightly to 76.2% in 2015. In COPD the usage was significantly lower, starting at 
18.1% in 1995 and increasing to a maximum of 70.7% in 2011, followed by a decrease to 62.7% in 2015. Aspirin 
usage in non-COPD increased slowly from 62.5% in 1995 to a plateau of approximately 83% from 2004 and onward. 
In COPD aspirin usage was slightly lower and declined from 81.2% in 2009 to 74.0% in 2015. Statin usage in non-
COPD increased rapidly from 5% in 1995 to a plateau of just below 85% from 2007 and onward. In COPD statin 
usage was consistently lower, and stagnated at a level of around 70% from 2007 and onward.  
Sensitivity analyses of patients with validated diagnoses of STEMI and NSTEMI showed overall 
similar trends for all three medications as for the entire study population, however undertreatment in COPD was less 
clear in patients with STEMI (supplementary Table S4a-c). 
 
Factors associated with non-use of medication in COPD 
Multivariable logistic regression analysis showed that COPD was associated with significantly increased odds for 
non-use of beta-blockers (OR 1.86 [95%CI 1.76-1.97; P<0.001]), aspirin (OR 1.24 [1.16-1.32; P<0.001]), and statins 
(OR 1.50 [1.41-1.59; P<0.001]) from 2006 to 2015. Analyses from 1995 to 2005 showed overall similar associations 
(supplementary Table S5).   
Figure 3 illustrates multivariable adjusted odds ratios for non-use of medication among patients with 
COPD from 2006 to 2015. Risk factors for non-use of beta-blockers included increasing age, female sex, use of 
multiple inhaled medications, frequent exacerbations of COPD, cerebrovascular disease, asthma, and depression. In 
the subgroup analysis of 937 patients with complete clinical data from 2008-2015, high GOLD class, and high 
mMRC dyspnoea score were associated with non-use of beta-blockers (Figure 4).  
Risk factors for non-use of aspirin in patients with COPD from 2006 to 2015 were atrial fibrillation, 
angina, hypertension, peripheral vascular disease, cerebrovascular disease, cancer, and renal failure (Figure 3), and 
there was a trend towards association for frequent COPD exacerbations. High mMRC dyspnoea score was also a risk 
factor (Figure 4), and conversely, low and medium income was associated with increased usage of aspirin (Figure 3). 
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In regard to statins, high age, female sex, heart failure, atrial fibrillation, cancer, renal failure, depression, frequent 
COPD exacerbations, low and medium income, and increasing mMRC dyspnoea score were risk factors for non-use 
from 2006 to 2015 (Figures 3 and 4).  
Sensitivity analyses of factors associated with non-use of medications were overall consistent with 
the main analyses and included analyses in patients with COPD stratified by STEMI and NSTEMI from 1995 to 
2005 and 2006 to 2015 (supplementary Tables S7a-d), univariable analyses in patients with COPD and clinical data 
available (supplementary Table S8), and multivariable analyses of factors associated with non-use of medications in 
patients with COPD and clinical data available stratified by STEMI vs NSTEMI (supplementary Tables  S9a-b). 
 
DISCUSSION 
Main findings 
In this large, nationwide cross-sectional study we showed that beta-blockers, and to a lesser extent aspirin and 
statins, were systematically underutilized by patients with COPD following hospitalization for first-time MI. 
Although there has been an overall increase in the utilization of secondary prevention medications during the study 
period, we demonstrated a consistent gap in utilization between patients with and without COPD for all three 
medications. Similar trends were observed in patients with STEMI and NSTEMI. While the overall uptake of beta-
blockers and aspirin was already substantial by the beginning of the study period, statin usage was very low and 
subsequently increased rapidly. This possibly reflects the publication of the Scandinavian Simvastatin Survival Study 
in 1994, which was the first large trial demonstrating that lipid lowering therapy reduces mortality after MI.23 
Evidence of the effectiveness of beta-blockers and aspirin emerged during the 1980s,24 and their use have 
subsequently been implemented gradually, however somewhat slowly for beta-blockers and in particular in patients 
with concurrent COPD. The majority of beta-blockers utilized were beta-1-selective in both COPD and non-COPD. 
COPD was a significant risk factor for non-use of medications, especially beta-blockers. 
Additionally, when analysing patients with COPD we found that frequent exacerbations and high dyspnoea score 
were general risk factors for non-use of medications. These findings implicate that there is a general reluctance to 
prescribing secondary prevention medications to patients with COPD and that severe symptom burden of COPD 
increases the reluctance. Underutilization in patients with severe COPD might be particularly unfortunate as 
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increasing COPD severity is a risk factor for cardiovascular morbidity and mortality,25 making secondary prevention 
medications particular important in these patients.  
Concerning beta-blockers, we showed that multiple indicators of COPD severity and symptom 
burden (GOLD class, mMRC dyspnoea score, number of long-acting inhaled medications, and frequent 
exacerbations) were significant risk-factors for non-use. This supports the hypothesis that underutilization of beta-
blockers in COPD is related to physicians concerns about bronchoconstriction. These concerns are unwarranted 
according to a Cochrane review updated in 2010 concluding that cardioselective beta-blockers are safe in COPD,26 
however, this have been challenged in a recent review based on new trials of beta-blockers in COPD.13 
Patients with COPD had lower income, which is a marker of socioeconomic status. We found that 
low and medium income were associated with non-use of aspirin from 2006 to 2015. However, this association was 
not present for beta-blockers in this time period and in regard to statins low income was associated with increased 
statin usage, which indicate that low income is not a general risk factor for non-use of secondary prevention 
medications.  
 
Comparison with previous studies 
The present study is, to our knowledge, the first to analyse the utilization of secondary prevention medications using 
redeemed prescriptions following hospitalisation for MI in patients with and without COPD. Previous studies have 
investigated in-hospital medication and prescription rates at discharge after MI,5–7,9–12,27 whereas one study 
investigated medication usage shortly (0.5 to 14 days) after admission among patients with MI and heart failure 
enrolled in randomised trials.28 Thus, the results of the latter study are likely to mirror the prescribed medications at 
discharge, and the selection of the study population may limit the generalisability of the results. Previous studies 
have shown great variation in estimates of beta-blocker utilization; in early studies from 1998 and 2005 the 
utilization of beta-blockers among patients with MI and COPD was only 22.1% and 16.0%,11,12 respectively - 
whereas studies from the past ten years indicate an increasing trend in the utilization of beta-blockers ranging from 
38.6% to 84.1%.5–7,9,10,27 The present study is in accordance with this, demonstrating an increasing utilization of beta-
blockers from 1995 to 2011. However, since 2012 the utilization of beta-blockers declined in patients with and 
without COPD, whereas aspirin and statin utilization was fairly constant. This might reflect a current discussion 
about the importance of beta-blockers following MI.22  
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Our findings of risk factors for non-use of secondary prevention medications among patient with 
COPD confirms and extends the findings of two previous studies assessing predictors for beta-blocker usage.6,7 We 
found that female sex and increasing age were risk factors for non-use of beta-blockers and statins. Underutilization 
in elderly might be caused by a concern about increased risk of adverse effects; however this hypothesis does not 
explain the underutilization among females. We found an association between various comorbidities and non-use of 
medications, which also is in correspondence with the previous studies.6,7 
Concurrent asthma was a risk-factor for non-use of beta-blockers, most likely due to added fear for 
bronchoconstriction beyond the concerns arising from COPD. However, according to a meta-analysis of randomised 
controlled trials, cardio-selective beta-blockers do not produce clinically significant adverse respiratory effects in 
patients with mild to moderate reactive airway disease.29 
 
Strengths and limitations 
By defining medication usage as redeemed prescriptions after discharge, our results reflect the real-life utilization of 
the medications, in contrast to in-hospital medication or prescriptions at discharge, which might over-estimate the 
actual utilization because patients might not redeem submitted prescriptions. The long study period of 21 years 
allowed us to investigate the long term trends of medication utilization. In this period guidelines for treatment of MI 
have been updated a number of times, however this does not affect our conclusions as we focussed on the differences 
in utilization of medications between patients with and without COPD, rather than the population as a whole. We 
analysed several indicators of COPD severity including exacerbations, numbers of long-acting inhaled medications, 
GOLD class, and dyspnoea score to estimate the association with non-use of secondary prevention medications. We 
believe that this improves the validity of our findings.  
A possible limitation of this study is that we did not have complete data on GOLD class, dyspnoea 
score,  smoking status, and BMI on all patients with COPD where complete data were only available in 937 patients. 
These data are obtained during outpatient visits in COPD hospital clinics i.e. data are missing in patients with a 
COPD diagnosis recorded only during hospital admissions. Diagnoses of MI and COPD have shown high validity in 
the registries, however there is an underrecording of COPD during hospitalisations with other acute respiratory 
disorders than COPD with a negative predictive value of 81%.19 Further, Danish administrative registers do not hold 
information on patient/physician preference or actual indication of therapy. 
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Conclusions 
Secondary prevention with beta-blockers, and to a lesser extent aspirin and statins, was systematically underutilized 
by patients with chronic obstructive pulmonary disease (COPD) following first-time hospitalisation for myocardial 
infarction during years 1995-2015 despite an overall increase in the utilization. Increasing severity of COPD was a 
risk factor for non-use of all three medications, in particular beta-blockers. This supports the hypothesis that 
undertreatment with beta-blockers in COPD is related to concerns about bronchoconstriction, whereas 
underutilization of aspirin and statins indicate a general reluctance to prescribing secondary prevention medications 
to patients with COPD. COPD patients is a high risk population where adherence to treatment guidelines is of 
particular importance. Clinicians involved in the cardiac rehabilitation and primary care physicians overseeing the 
follow-up following a MI should take particular care regarding the use of secondary prevention in the COPD 
population. This should be ensured in order to improve the uptake of potential lifesaving medication and thus work 
towards increased quality of care. 
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FIGURES AND TABLES 
Figure 1.  Overview of the study population. 
  Abbreviations: COPD = chronic obstructive pulmonary disease. 
Table 1.  Characteristics of 140,278 patients following myocardial infarction from 1995 to 2015 stratified by 
chronic obstructive pulmonary disease (COPD). 
Table 2.  Characteristics of 13,496 patients with chronic obstructive pulmonary disease following first-time 
myocardial infarction from 1995 to 2015. 
Figure 2a.  Temporal trends of beta-blocker usage after first-time myocardial infarction in patients with and 
without chronic obstructive pulmonary disease (COPD) from 1995 to 2015. Bands represent 95% 
confidence intervals. 
Figure 2b. Temporal trends of aspirin usage after first-time myocardial infarction in patients with and without 
chronic obstructive pulmonary disease (COPD) from 1995 to 2015. Bands represent 95% confidence 
intervals. 
Figure 2c.  Temporal trends of statin usage after first-time myocardial infarction in patients with and without 
chronic obstructive pulmonary disease (COPD) from 1995 to 2015. Bands represent 95% confidence 
intervals. 
Figure 3.  Factors associated with non-use of beta-blockers, aspirin, and statins in 6,979 patients with chronic 
obstructive pulmonary disease (COPD) following myocardial infarction from 2006 to 2015. Odds 
ratios >1.00 indicate an increased risk of non-use of medication. 
Figure 4.  Factors associated with non-use of beta-blockers, aspirin, and statins in 937 patients with chronic 
obstructive pulmonary disease and complete clinical data, following myocardial infarction from 
2008 to 2015. Odds ratios are estimated by multivariable logistic regression including the presented 
factors. Odds ratios >1.00 indicate an increased risk of non-use of medication. 
Abbreviations: GOLD = Global Initiative for Chronic Obstructive Lung Disease classification of 
airflow limitation severity (GOLD 1 - mild: FEV1% [forced expiratory volume in 1 second 
expressed as percentage of predicted] ≥ 80; GOLD 2 - moderate: 50 ≤FEV1% <80; GOLD 3 - 
severe: 30 ≤FEV1% <50; GOLD 4 - very severe: FEV1% <30); mMRC = modified Medical 
Research Council dyspnoea score; BMI = body mass index 
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SUPPLEMENTARY DATA 
Table S1.  Diagnoses and medicines used for definition of comorbidities. 
Abbreviations: ICD10 = 10th revision of the International Classification of Diseases system. ICD8 
= 8th revision of the International Classification of Diseases system. ATC = Anatomical Therapeutic 
Chemical Classification System. 
Table S2. Definition of medications. 
Abbreviations: ATC = Anatomical Therapeutic Chemical Classification System 
Table S3.  Characteristics of patients following myocardial infarction (MI) from 1995 to 2015 stratified by ST-
segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI), and chronic 
obstructive pulmonary disease (COPD). 
Figure S4a.  Temporal trends of beta-blocker usage after myocardial infarction from 1995 to 2015 in patients 
with and without chronic obstructive pulmonary disease (COPD) and (1) ST-segment elevation 
myocardial infarction (STEMI) and (2) non-STEMI (NSTEMI). Bands represent 95% confidence 
intervals. 
Figure S4b. Temporal trends of aspirin usage after myocardial infarction from 1995 to 2015 in patients with and 
without chronic obstructive pulmonary disease (COPD) and (1) ST-segment elevation myocardial 
infarction (STEMI) and (2) non-STEMI (NSTEMI). Bands represent 95% confidence intervals. 
Figure S4c.  Temporal trends of statins usage after myocardial infarction from 1995 to 2015 in patients with and 
without chronic obstructive pulmonary disease (COPD) and (1) ST-segment elevation myocardial 
infarction (STEMI) and (2) non-STEMI (NSTEMI). Bands represent 95% confidence intervals. 
Table S5.  Association between chronic obstructive pulmonary disease (COPD) and non-use of beta-blockers, 
aspirin, and statins in 75,087 patients following myocardial infarction from 1995 to 2005. Odds 
ratios >1.00 indicate an increased risk of non-use of medication. 
Table S6.  Factors associated with non-use of beta-blockers, aspirin, and statins in 6,517 patients with chronic 
obstructive pulmonary disease (COPD) following myocardial infarction from 1995 to 2005. Odds 
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ratios >1.00 indicate an increased risk of non-use of medication. 
* Frequent COPD exacerbations were defined as ≥2 exacerbations and/or ≥1 exacerbation leading to 
hospitalisation during last year. 
Table S7a.  Factors associated with non-use of beta-blockers, aspirin, and statins in 298 patients with chronic 
obstructive pulmonary disease (COPD) following ST-segment elevation myocardial infarction 
(STEMI) from 1995 to 2005. Odds ratios >1.00 indicate an increased risk of non-use of medication. 
* Frequent COPD exacerbations were defined as ≥2 exacerbations and/or ≥1 exacerbation leading to 
hospitalisation during last year. 
Table S7b.  Factors associated with non-use of beta-blockers, aspirin, and statins in 970 patients with chronic 
obstructive pulmonary disease (COPD) following ST-segment elevation myocardial infarction 
(STEMI) from 2006 to 2015. Odds ratios >1.00 indicate an increased risk of non-use of medication. 
* Frequent COPD exacerbations were defined as ≥2 exacerbations and/or ≥1 exacerbation leading to 
hospitalisation during last year. 
Table S7c.  Factors associated with non-use of beta-blockers, aspirin, and statins in 1,905 patients with chronic 
obstructive pulmonary disease (COPD) following non-ST-segment elevation myocardial infarction 
(NSTEMI) from 1995 to 2005. Odds ratios >1.00 indicate an increased risk of non-use of 
medication. 
* Frequent COPD exacerbations were defined as ≥2 exacerbations and/or ≥1 exacerbation leading to 
hospitalisation during last year. 
Table S7d.  Factors associated with non-use of beta-blockers, aspirin, and statins in 3,449 patients with chronic 
obstructive pulmonary disease (COPD)  following non-ST-segment elevation myocardial infarction 
(NSTEMI) from 2006 to 2015. Odds ratios >1.00 indicate an increased risk of non-use of 
medication. 
* Frequent COPD exacerbations were defined as ≥2 exacerbations and/or ≥1 exacerbation leading to 
hospitalisation during last year. 
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Table S8.  Factors associated with non-use of beta-blockers, aspirin, and statins in patients with chronic 
obstructive pulmonary disease (COPD) and clinical data available following myocardial infarction 
from 2008 to 2015. Odds ratios are estimated by univariable logistic regression analyses. Odds ratios 
>1.00 indicate an increased risk of non-use of medication. 
Abbreviations: GOLD = Global Initiative for Chronic Obstructive Lung Disease classification of 
airflow limitation severity (GOLD 1 - mild: FEV1% [forced expiratory volume in 1 second 
expressed as percentage of predicted] ≥ 80; GOLD 2 - moderate: 50 ≤FEV1% <80; GOLD 3 - 
severe: 30 ≤FEV1% <50; GOLD 4 - very severe: FEV1% <30); mMRC = modified Medical 
Research Council dyspnoea score; BMI = body mass index. 
Table S9a.  Factors associated with non-use of beta-blockers, aspirin, and statins in 109 patients with chronic 
obstructive pulmonary disease (COPD) and clinical data available following ST-segment elevation 
myocardial infarction (STEMI) from 2008 to 2015. Odds ratios are estimated by multivariable 
logistic regression including the presented factors. Odds ratios >1.00 indicate an increased risk of 
non-use of medication. 
Abbreviations: GOLD = Global Initiative for Chronic Obstructive Lung Disease classification of 
airflow limitation severity (GOLD 1 - mild: FEV1% [forced expiratory volume in 1 second 
expressed as percentage of predicted] ≥ 80; GOLD 2 - moderate: 50 ≤FEV1% <80; GOLD 3 - 
severe: 30 ≤FEV1% <50; GOLD 4 - very severe: FEV1% <30); mMRC = modified Medical 
Research Council dyspnoea score; BMI = body mass index. 
Table S9b.  Factors associated with non-use of beta-blockers, aspirin, and statins in 520 patients with chronic 
obstructive pulmonary disease (COPD) and clinical data available following non-ST-segment 
elevation myocardial infarction (NSTEMI) from 2008 to 2015. Odds ratios are estimated by 
multivariable logistic regression including the presented factors. Odds ratios >1.00 indicate an 
increased risk of non-use of medication. 
Abbreviations: GOLD = Global Initiative for Chronic Obstructive Lung Disease classification of 
airflow limitation severity (GOLD 1 - mild: FEV1% [forced expiratory volume in 1 second 
expressed as percentage of predicted] ≥ 80; GOLD 2 - moderate: 50 ≤FEV1% <80; GOLD 3 - 
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severe: 30 ≤FEV1% <50; GOLD 4 - very severe: FEV1% <30); mMRC = modified Medical 
Research Council dyspnoea score; BMI = body mass index. 
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TABLES AND FIGURES 
Figure 1. Overview of the study population.  
 
Abbreviations: COPD = chronic obstructive pulmonary disease.   
COPD 
(n=13,496 [9.6%]) 
No COPD 
(n=126,782 [90.4%]) 
Study population 
(n=140,278) 
Inclusion criteria: 
First-time myocardial 
infarction 1995-2015 
(n=176,684) 
Exclusion: 
Death during admission 
or within 90 days from 
discharge (n=34,061) 
 
Emigration within 90 
days from discharge 
(n=38) 
Discharged <90 days 
from end of follow-up 
(n=1,672) 
Non-complete data 
(n=635) 
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Table 1. Characteristics of 140,278 patients following myocardial infarction from 1995 to 2015 stratified by chronic obstructive 
pulmonary disease (COPD). 
 No COPD COPD P Value 
N 126782 13496   
Age, median (IQR) 67 (57, 77) 74 (67, 80) <0.001 
Male 82257 (64.9%) 7167 (53.1%) <0.001 
Medication usage after MI    
Beta-blockers 96592 (76.2%) 7184 (53.2%) <0.001 
Aspirin 99902 (78.8%) 9974 (73.9%) <0.001 
Statins 78511 (61.9%) 7215 (53.5%) <0.001 
Previous medication    
Beta-blockers 21809 (17.2%) 2462 (18.2%) 0.002 
Aspirin 27463 (21.7%) 4476 (33.2%) <0.001 
Statins 19349 (15.3%) 2812 (20.8%) <0.001 
Type of MI    
STEMI 18671 (14.7%) 1268 (9.4%) <0.001 
NSTEMI 40352 (31.8%) 5354 (39.7%)  
Unspecified 67759 (53.4%) 6874 (50.9%)   
Comorbidities    
Heart failure 19592 (15.5%) 4082 (30.2%) <0.001 
Atrial fibrillation 12661 (10.0%) 2609 (19.3%) <0.001 
Angina pectoris 26911 (21.2%) 3470 (25.7%) <0.001 
Hypertension 36159 (28.5%) 4852 (36.0%) <0.001 
Diabetes mellitus 17883 (14.1%) 2390 (17.7%) <0.001 
Peripheral vascular disease 7051 (5.6%) 1569 (11.6%) <0.001 
Cerebrovascular disease 10949 (8.6%) 1638 (12.1%) <0.001 
Cancer 9653 (7.6%) 1609 (11.9%) <0.001 
Renal failure 4370 (3.4%) 824 (6.1%) <0.001 
Asthma 1400 (1.1%) 1901 (14.1%) <0.001 
Depression 12433 (9.8%) 2710 (20.1%) <0.001 
Income    
Low 40352 (31.8%) 6408 (47.5%) <0.001 
Medium 41910 (33.1%) 4849 (35.9%)  
High 44520 (35.1%) 2239 (16.6%)   
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Table 2. Characteristics of 13,496 patients with chronic obstructive pulmonary disease following first-time myocardial infarction from 1995 to 2015. 
 Beta-blockers  Aspirin  Statins 
 Non-user User P value  Non-user User P value  Non-user User P value 
N 6312 7184     3522 9974     6281 7215   
Age, median (IQR) 74 (68, 81) 73 (66, 80) <0.001  74 (67, 80) 74 (67, 80) 0.160  76 (69, 82) 72 (65, 79) <0.001 
Male 3072 (48.7%) 4095 (57.0%) <0.001   1842 (52.3%) 5325 (53.4%) 0.270   3234 (51.5%) 3933 (54.5%) 0.000 
Medication usage after MI            
Beta-blockers 0 (0.0%) 7184 (100.0%) <0.001   1466 (41.6%) 5718 (57.3%) <0.001   2263 (36.0%) 4921 (68.2%) <0.001 
Aspirin 4256 (67.4%) 5718 (79.6%) <0.001  0 (0.0%) 9974 (100.0%) <0.001  4088 (65.1%) 5886 (81.6%) <0.001 
Statins 2294 (36.3%) 4921 (68.5%) <0.001   1329 (37.7%) 5886 (59.0%) <0.001   0 (0.0%) 7215 (100.0%) <0.001 
Previous medication            
Beta-blockers 545 (8.6%) 1917 (26.7%) <0.001   768 (21.8%) 1694 (17.0%) <0.001   957 (15.2%) 1505 (20.9%) <0.001 
Aspirin 1957 (31.0%) 2519 (35.1%) <0.001  1241 (35.2%) 3235 (32.4%) 0.002  1987 (31.6%) 2489 (34.5%) 0.000 
Statins 997 (15.8%) 1815 (25.3%) <0.001   838 (23.8%) 1974 (19.8%) <0.001   539 (8.6%) 2273 (31.5%) <0.001 
Long acting inhalation therapy            
None 2093 (33.2%) 3277 (45.6%) <0.001   1405 (39.9%) 3965 (39.8%) 0.031   2602 (41.4%) 2768 (38.4%) <0.001 
Mono 993 (15.7%) 911 (12.7%)   518 (14.7%) 1386 (13.9%)   946 (15.1%) 958 (13.3%)  
Dual 2139 (33.9%) 1781 (24.8%)     1052 (29.9%) 2868 (28.8%)     1919 (30.6%) 2001 (27.7%)   
Triple 1087 (17.2%) 1215 (16.9%)   547 (15.5%) 1755 (17.6%)   814 (13.0%) 1488 (20.6%)  
Frequent exacerbations* 2123 (33.6%) 1564 (21.8%) <0.001   996 (28.3%) 2691 (27.0%) 0.140   1848 (29.4%) 1839 (25.5%) <0.001 
Comorbidities            
Heart failure 1831 (29.0%) 2251 (31.3%) 0.003   1126 (32.0%) 2956 (29.6%) 0.010   1955 (31.1%) 2127 (29.5%) 0.038 
Atrial fibrillation 1176 (18.6%) 1433 (19.9%) 0.053  889 (25.2%) 1720 (17.2%) <0.001  1322 (21.0%) 1287 (17.8%) <0.001 
Angina pectoris 1443 (22.9%) 2027 (28.2%) <0.001   980 (27.8%) 2490 (25.0%) 0.001   1364 (21.7%) 2106 (29.2%) <0.001 
Hypertension 1824 (28.9%) 3028 (42.1%) <0.001  1344 (38.2%) 3508 (35.2%) 0.002  1752 (27.9%) 3100 (43.0%) <0.001 
Diabetes mellitus 991 (15.7%) 1399 (19.5%) <0.001   691 (19.6%) 1699 (17.0%) 0.001   944 (15.0%) 1446 (20.0%) <0.001 
Peripheral vascular disease 646 (10.2%) 923 (12.8%) <0.001  482 (13.7%) 1087 (10.9%) <0.001  592 (9.4%) 977 (13.5%) <0.001 
Cerebrovascular disease 776 (12.3%) 862 (12.0%) 0.600   556 (15.8%) 1082 (10.8%) <0.001   808 (12.9%) 830 (11.5%) 0.016 
Cancer 754 (11.9%) 855 (11.9%) 0.940  472 (13.4%) 1137 (11.4%) 0.002  793 (12.6%) 816 (11.3%) 0.019 
Renal failure 331 (5.2%) 493 (6.9%) <0.001   298 (8.5%) 526 (5.3%) <0.001   391 (6.2%) 433 (6.0%) 0.590 
Asthma 1080 (17.1%) 821 (11.4%) <0.001  533 (15.1%) 1368 (13.7%) 0.038  889 (14.2%) 1012 (14.0%) 0.830 
Depression 1350 (21.4%) 1360 (18.9%) 0.0004   729 (20.7%) 1981 (19.9%) 0.290   1318 (21.0%) 1392 (19.3%) 0.015 
Income            
Low 3107 (49.2%) 3301 (45.9%) <0.001   1634 (46.4%) 4774 (47.9%) 0.230   3232 (51.5%) 3176 (44.0%) <0.001 
Medium 2236 (35.4%) 2613 (36.4%)   1277 (36.3%) 3572 (35.8%)   2203 (35.1%) 2646 (36.7%)  
High 969 (15.4%) 1270 (17.7%)     611 (17.3%) 1628 (16.3%)     846 (13.5%) 1393 (19.3%)   
* Frequent exacerbations were defined as ≥2 exacerbations and/or ≥1 exacerbation leading to hospitalisation during last year.     
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Figure 2a. Temporal trends of beta-blocker usage after first-time myocardial infarction in patients with and without chronic obstructive 
pulmonary disease (COPD) from 1995 to 2015. Bands represent 95% confidence intervals. 
 
 
 
Figure 2b. Temporal trends of aspirin usage after first-time myocardial infarction in patients with and without chronic obstructive 
pulmonary disease (COPD) from 1995 to 2015. Bands represent 95% confidence intervals. 
  
 
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Non-COPD (% users) 45.8 54.9 63.2 65.8 72.4 79.1 81.6 81.6 82.3 82.6 82.6 80.8 81.9 82.7 81.6 80.7 81.5 81.3 79.0 76.1 76.2
COPD (% users) 18.1 18.5 19.2 26.1 30.9 40.2 41.5 46.5 50.9 53.7 58.8 55.6 59.7 62.8 65.4 68.6 70.7 69.4 67.2 64.4 62.7
Year
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Non-COPD (% users) 62.5 66.9 68.6 69.9 71.2 71.2 75.1 77.9 80.5 82.9 83.1 84.5 85.9 86.1 84.8 84.1 84.3 85.8 83.2 81.9 83.1
COPD (% users) 59.2 64.3 68.8 64.7 65.3 68.8 70.1 73.7 72.8 77.2 79.5 78.8 79.5 79.6 81.2 78.4 76.1 76.4 70.1 71.7 74.0
Year
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Figure 2c. Temporal trends of statin usage after first-time myocardial infarction in patients with and without chronic obstructive 
pulmonary disease (COPD) from 1995 to 2015. Bands represent 95% confidence intervals. 
 
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Non-COPD (% users) 5.4 9.0 13.0 19.2 31.5 38.4 47.4 62.3 72.6 77.4 81.1 82.0 82.7 84.5 82.5 82.3 83.6 84.9 85.3 83.8 85.3
COPD (% users) 3.4 4.6 5.5 12.2 17.5 22.0 25.8 41.9 51.4 62.4 65.9 69.5 70.0 74.3 72.1 71.6 69.5 71.0 72.4 70.0 73.6
Year
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Figure 3. Factors associated with non-use of beta-blockers, aspirin, and statins in 6,979 patients with chronic obstructive pulmonary disease (COPD) following myocardial infarction 
from 2006 to 2015. Odds ratios >1.00 indicate an increased risk of non-use of medication. 
 
Age
18-59 years 1.00 (reference) - 1.00 (reference) - 1.00 (reference) -
60-69 years 1.12 (0.92-1.37) 0.246 1.05 (0.84-1.31) 0.679 1.04 (0.84-1.29) 0.739
70-79 years 1.24 (1.02-1.50) 0.028 1.11 (0.89-1.38) 0.346 0.93 (0.75-1.14) 0.491
80+ years 1.49 (1.23-1.81) <0.001 1.04 (0.83-1.30) 0.743 1.86 (1.51-2.29) <0.001
Sex
Female 1.30 (1.17-1.44) <0.001 1.04 (0.93-1.17) 0.502 1.18 (1.06-1.32) 0.003
Long acting inhaled medication
None 1.00 (reference) - 1.00 (reference) - 1.00 (reference)
Mono 1.11 (0.93-1.32) 0.241 0.94 (0.78-1.15) 0.561 0.88 (0.73-1.06) 0.190
Dual 1.37 (1.20-1.57) <0.001 1.16 (1.00-1.35) 0.054 1.01 (0.87-1.16) 0.917
Triple 1.44 (1.25-1.66) <0.001 1.08 (0.92-1.27) 0.347 1.14 (0.98-1.32) 0.091
Frequent COPD exacerbations 1.51 (1.34-1.70) <0.001 1.14 (1.00-1.30) 0.058 1.28 (1.13-1.45) <0.001
Comorbidities
Heart failure 0.79 (0.71-0.88) <0.001 0.98 (0.87-1.11) 0.732 1.18 (1.05-1.32) 0.006
Atrial fibrillation 0.93 (0.82-1.05) 0.232 1.83 (1.60-2.08) <0.001 1.51 (1.33-1.72) <0.001
Angina 1.00 (0.89-1.12) 0.983 1.19 (1.05-1.35) 0.008 0.85 (0.75-0.96) 0.009
Hypertension 0.73 (0.65-0.81) <0.001 1.23 (1.09-1.39) 0.001 0.89 (0.79-0.99) 0.040
Diabetes 1.04 (0.91-1.19) 0.544 1.10 (0.95-1.26) 0.202 0.86 (0.75-0.99) 0.041
Peripheral vascular disease 0.90 (0.77-1.04) 0.162 1.19 (1.01-1.39) 0.033 0.80 (0.68-0.94) 0.007
Cerebrovascular disease 1.23 (1.05-1.43) 0.010 1.41 (1.20-1.66) <0.001 1.04 (0.89-1.23) 0.608
Cancer 1.08 (0.94-1.25) 0.281 1.32 (1.12-1.54) 0.001 1.37 (1.18-1.59) <0.001
Renal failure 1.13 (0.92-1.37) 0.240 1.46 (1.20-1.78) <0.001 1.59 (1.30-1.93) <0.001
Asthma 1.18 (1.02-1.37) 0.027 1.04 (0.88-1.23) 0.655 1.01 (0.86-1.18) 0.923
Depression 1.32 (1.17-1.48) <0.001 1.07 (0.93-1.22) 0.353 1.52 (1.34-1.71) <0.001
Income
Low 0.92 (0.79-1.06) 0.254 0.82 (0.69-0.97) 0.018 1.36 (1.15-1.61) <0.001
Medium 0.94 (0.81-1.09) 0.381 0.90 (0.76-1.06) 0.215 1.31 (1.10-1.54) 0.002
High 1.00 (reference) - 1.00 (reference) - 1.00 (reference) -
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(95% CI) P  Value
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(95% CI) P  Value
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Figure 4. Factors associated with non-use of beta-blockers, aspirin, and statins in 937 patients with chronic obstructive pulmonary disease and complete clinical data, following 
myocardial infarction from 2008 to 2015. Odds ratios are estimated by multivariable logistic regression including the presented factors. Odds ratios >1.00 indicate an increased risk 
of non-use of medication. 
 
Abbreviations: GOLD = Global Initiative for Chronic Obstructive Lung Disease classification of airflow limitation severity (GOLD 1 - mild: FEV1% [forced expiratory volume in 1 
second expressed as percentage of predicted] ≥ 80; GOLD 2 - moderate: 50 ≤FEV1% <80; GOLD 3 - severe: 30 ≤FEV1% <50; GOLD 4 - very severe: FEV1% <30);  
mMRC = modified Medical Research Council dyspnoea score; BMI = body mass index 
Odds ratio 
(95% CI)
P 
Value
Odds ratio
 (95% CI)
P 
Value
Odds ratio 
(95% CI)
P 
Value
GOLD
GOLD 1-2 1.00 (reference) - 1.00 (reference) - 1.00 (reference) -
GOLD 3 1.02 (0.74-1.39) 0.915 0.89 (0.63-1.25) 0.490 1.06 (0.76-1.49) 0.718
GOLD 4 1.54 (1.03-2.32) 0.038 0.89 (0.57-1.39) 0.598 0.70 (0.45-1.10) 0.125
mMRC dyspnoea score
mMRC 0-1 1.00 (reference) - 1.00 (reference) - 1.00 (reference) -
mMRC 2 1.34 (0.94-1.91) 0.109 1.28 (0.86-1.9) 0.218 1.91 (1.28-2.86) 0.002
mMRC 3-4 1.44 (1.00-2.07) 0.049 1.51 (1.02-2.25) 0.042 2.54 (1.69-3.81) <0.001
Smoking
Non smoker 1.00 (reference) - 1.00 (reference) - 1.00 (reference) -
Smoker 0.96 (0.72-1.27) 0.751 0.75 (0.55-1.03) 0.074 1.04 (0.77-1.41) 0.802
BMI
10 - 18.4 1.27 (0.80-2.02) 0.313 1.25 (0.75-2.07) 0.391 1.50 (0.93-2.41) 0.094
18.5 - 24.9 1.00 (reference) - 1.00 (reference) - 1.00 (reference) -
25+ 0.75 (0.57-1.00) 0.052 1.03 (0.75-1.41) 0.850 0.64 (0.47-0.88) 0.006
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